Ferrous Gluconate: Uses, Side Effects, Dosage - Drugvu

ℹ️ Compiled from public regulatory records · Last regulator revision: April 24, 2026🚩 Report this page

Ferrous Gluconate

Iron Bivalent, Oral Preparations

GB MHRA

Drug class: Iron Bivalent, Oral Preparations
Availability: See label
Markets covered: 1
Products on record: 10

Overview

Ferrous Gluconate is an active pharmaceutical ingredient in the Iron Bivalent, Oral Preparations group (B03AA). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.

Regulatory status by market

Market	Regulator	Products	Last revision
GB United Kingdom	MHRA	10	April 24, 2026

GBUnited Kingdom· MHRA

10 products

Uses

GBOfficial regulatory label· revised September 19, 2025[1]

Ferrous Gluconate 300mg Tablets are indicated for the prevention and treatment of iron deficiency states.

How to take

Drug interactions

Known interactions involving Ferrous Gluconate. Select one for details. This list is informational and not a complete interaction checker.

Bictegravir Dimercaprol Dolutegravir Alendronate Aluminum Hydroxide Baloxavir Marboxil Calcium Carbonate Cefdinir Chloramphenicol Cinoxacin Ciprofloxacin Deferiprone Delafloxacin Demeclocycline Dexlansoprazole Doxycycline Eltrombopag Enoxacin Entacapone Esomeprazole Ferric Carboxymaltose Ferric Derisomaltose Ferumoxytol Gatifloxacin Gemifloxacin Grepafloxacin Ibandronate Iron Sucrose Lansoprazole Lanthanum Carbonate Levodopa Levofloxacin Levothyroxine Liothyronine Lomefloxacin Magaldrate Magnesium Carbonate Magnesium Hydroxide Magnesium Oxide Methyldopa Minocycline Moxifloxacin Norfloxacin Ofloxacin Omadacycline Omeprazole Oxytetracycline Pantoprazole Patiromer Penicillamine Quinapril Rabeprazole Risedronic Acid Sarecycline Sodium Bicarbonate Sodium Citrate Sodium Ferric Gluconate Complex Sodium Sulfate Sparfloxacin Tetracycline Tiludronic Acid Trovafloxacin Vitamin E Cimetidine Mycophenolate Mofetil Mycophenolic Acid Zinc Acetate Zinc Gluconate Zinc Sulfate

Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.

Sources & citations

[1]MHRA (UK) · PL204160073 · revised September 19, 2025

Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.

Side effects & warnings

GBOfficial regulatory label· Adverse reactions· revised September 19, 2025[1]

Large doses of iron may cause gastro-intestinal discomfort, anorexia, diarrhoea, nausea, heatburn and vomiting. These side effects have been reported to occur in up to 20% or more of patients treated and are related to the amount of elemental iron taken rather than the type of preparation.
Continued administration of ferrous gluconate may result in constipation and faecal impaction. Darkening of stools may occur. Higher doses of ferrous gluconate may have irritant and corrosive effects on the gastro-intestinal mucosa and necrosis and perforation may occur; stricture formation may subsequently follow.
Symptoms which may not appear for several hours, include epigastric pain, diarrhoea, vomiting and haematemesis. Circulatory failure may follow if diarrhoea and haemorrhage are severe. Rarely allergic reactions may occur.
Cardiac disorders Frequency ‘Not known’:
Kounis syndrome Reporting of suspected adverse reactions: Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.
uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

GBOfficial regulatory label· Warnings and precautions· revised September 19, 2025[1]

Large doses may have irritant/corrosive effect on gastro-intestinal mucosa which can lead to necrosis and perforation. Ferrous Gluconate should be used with caution in patients with haemolytic anaemia. Caution is required in the elderly, who may be at increased risk of serious adverse reactions.
g. gastric erosions or colonic carcinoma. Care should be exercised in patients with iron-absorption diseases. Patients post gastrectomy have poor absorption of iron. Caution is advised when prescribing iron preparations to individuals with history of peptic ulcer, and inflammatory bowel disease, including regional enteritis and ulcerative colitis and care should be exercised in patients with intestinal strictures and diverticulae.
Duration of treatment should generally not exceed 3 months after correction of anaemia. Co-existing deficiency of vitamin B12 or folic acid should be ruled out since combined deficiency produces microcytic blood film. Dental caries is a definite risk following long term treatment with this product.
Patients suffering from iron overload are particularly susceptible to infection. Treatment of iron overload should be with caution. Iron preparations colour the faeces black, which may interfere with tests used for detection of occult blood in the stools.
Hypersensitivity reactions Parenterally administered iron preparations can cause hypersensitivity reactions including serious and potentially fatal anaphylactic/anaphylactoid reactions. Hypersensitivity reactions have also been reported after previously uneventful doses of parenteral iron complexes.
8). These tablets contain sugar and should be administered with care to patients with diabetes. This product contains sucrose. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.
This product contains E124, E122 & E110 which may cause allergic reactions.
The label will state: ‘Important warning:
Contains iron. ’ This will appear on the front of the pack within a rectangle in which there is no other information.

This is not medical advice. Consult a qualified healthcare professional.

Overview

Regulatory status by market

GBUnited Kingdom· MHRA

Drug interactions

Drugs in the same class

Sources & citations